Effect and safety analysis of Allergovit standardized mite allergen immunotherapy in patients with allergic rhinitis.
- Author:
Xiaoming ZHAO
1
;
Huiqing WU
2
;
Lili LIN
2
;
Qianzu LIU
2
;
Xiaomin LI
2
;
Bin LUO
2
Author Information
1. Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China. zhaoxmzhao@aliyun.com
2. Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Animals;
Child;
Child, Preschool;
Female;
Humans;
Immunotherapy;
Male;
Middle Aged;
Pyroglyphidae;
immunology;
Quality of Life;
Retrospective Studies;
Rhinitis, Allergic;
Rhinitis, Allergic, Perennial;
therapy;
Treatment Outcome;
Vaccines;
adverse effects;
therapeutic use;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2013;27(20):1128-1131
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the effect and safety analysis of Allergovit standardized dust mite subcutaneous immunotherapy in patients with allergic rhinitis.
METHOD:From Jan 2006 to Jan 2009,425 patients with persistent were treated with Allergovit standardized dust mite allergen in 3 years, which data were retrospectively analyzed. The scores of the rhinoconjunctivitis quality of life were collected per-treatment and three years treatment. VAS (visual analogue scale) of all nasal symptoms and drug use scores were evaluated before treatment and every 6 weeks. The frequency of local and systemic reactions were recorded in the duration of dose escalation and maintenance.
RESULT:The Overall QOL were significantly improved after 3 years treatment [pre-treatment: 3.8 (2.9; 4.5); post-treatment: 1.1 (1.0; 2.0), P < 0.01]. VAS of all nasal symptoms and drug used scores decreased dramatically after escalation period [pro-treatment: 23. 7 (20.5; 27.8), 3.9 (3.2; 4.7); post-treatment: 2.1 (1.6; 2.2), 0(0;0), P < 0.01]. Local reaction's rate was 3.15%, the frequency systemic reaction's rate was 0.90%.
CONCLUSION:The standardized specific allergen immunotherapy for allergic rhinitis is safe and effective.
